Marshall Wace’s Lineage Cell Therapeutics LCTX Stock Holding History

Marshall Wace’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.68M	Sell	1,282,347 -1,782,686	-58%	-$2.46M	﹤0.01%	1947
2026 Q1	$4.84M	Buy	3,065,033 +1,702,972	+125%	+$2.87M	﹤0.01%	1323
2025 Q4	$2.27M	Buy	+1,362,061	New	+$2.36M	﹤0.01%	1517
2023 Q2	–	Sell	-55,646	Closed	-$83.5K	–	2732
2023 Q1	$83.5K	Buy	55,646 +18,528	+50%	+$25.9K	﹤0.01%	2511
2022 Q4	$43.4K	Sell	37,118 -6,709	-15%	-$8.46K	﹤0.01%	2843
2022 Q3	$50K	Buy	+43,827	New	+$64.4K	﹤0.01%	3241
2021 Q3	–	Sell	-186,940	Closed	-$533K	–	3247
2021 Q2	$533K	Buy	+186,940	New	+$484K	﹤0.01%	2098

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Marshall Wace's LCTX Position: Q2 2026 in Review

Marshall Wace reduced its Lineage Cell Therapeutics (LCTX) stake by 58% in Q2 2026, selling an estimated $2.46M and leaving 1,282,347 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #1947.

Marshall Wace first reported a position in LCTX in Q2 2021 and has held it in 7 quarters since. The position peaked at $4.84M in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Marshall Wace held 1,282,347 shares of Lineage Cell Therapeutics worth $1.68M as of Q2 2026.
Marshall Wace sold 1,782,686 Lineage Cell Therapeutics shares in Q2 2026, an estimated $2.46M.
Lineage Cell Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1947 holding.
Marshall Wace first reported a position in Lineage Cell Therapeutics in Q2 2021 and has held it in 7 quarters since.
Marshall Wace's Lineage Cell Therapeutics position peaked at $4.84M in Q1 2026.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.